Cardiac Arrest Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Cardiac Arrest Treatment Market is Segmented by Treatment (Drugs and Medical Devices), Distribution Channel, and Geography.

Cardiac Arrest Treatment Market Snapshot

Cardiac Arrest Treatment Market
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: >4.8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The cardiac arrest treatment market studied was anticipated to witness a CAGR of nearly 4.8%, during the forecast period. The major factors driving the growth of the market are the increasing prevalence of various coronary heart diseases, cardiomyopathy, which is leading to cardiac arrest deaths, favorable reimbursement initiatives, and a rise in the geriatric population. For instance, according to Global Health and Wellness Report published in 2018, nearly 40% of the adult population in the United States were diagnosed with a cardiovascular condition, which directly resulted in higher demand for highly efficient, immediate treatment, and better technological advanced cardiovascular devices, which is expected to fuel the growth of the market throughout the forecast period.

Scope of the Report

Cardiac arrest is an emergency situation when the heart fails to pump blood effectively, stops beating, along with loss of consciousness, and abnormal or absence of breathing in severe cases. The major factors that cause cardiac arrest are coronary artery disease, cardiomyopathy, long QT syndrome, and Brugada syndrome. Appropriate treatment must be provided to the patient immediately in such cases. Various drugs, like beta-blockers, anti-arrhythmic drugs, and medical devices, like defibrillators, are used to treat cardiac arrest.

By Treatment
Drugs
Vasopressors
Anti-arrhythmic Drugs
Anticholinergic Drugs
Antihypertensives
Other Drugs
Medical Devices
Cardiac Resynchronization Therapy (CRT)
Defibrillators
Other Medical Devices
By Distribution Channel
Hospitals
Pharmacies
Other Distribution Channels
Geography
North America
United states
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Drug Segment is Expected to Hold the Largest Market Share in the Cardiac Arrest Treatment Market

  • The drug segment is expected to witness the largest market share in the cardiac arrest treatment market during the forecast period. This dominance is due to the increased use of various drugs such as anticholinergics, beta-blockers, vasopressors, and fibrinolytic drugs owing to the rise in prescriptions by the cardiologists.
  • Furthermore, anti-arrhythmic drugs are widely used by most patients for the treatment of potential arrhythmia and during emergencies to save the person from heart failure or cardiac arrest. On the other hand, medical devices such as defibrillators and cardiac resynchronization therapy (CRT) are gaining attraction in recent years. They are anticipated to witness significant growth in the forecast period due to rising awareness among the patients. Furthermore, the growth can be attributed to the rise in usage by the people who are expected to face cardiac arrest problems in the near future.
Cardiac Arrest Treatment Market

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall cardiac arrest treatment market throughout the forecast period. The major factors attributing to the growth are a rise in the global prevalence of multiple cardiovascular indications like CAD, strokes, and atrial fibrillation, along with the increase of chronic diseases, such as diabetes and obesity, necessitating efficient cardiac arrest treatment. For instance, according to The American Heart Association, in 2018, nearly 92.1 million individuals in the country suffered from cardiovascular diseases. CAD was the primary cause of death that resulted in higher demand for better treatment technologies, driving the market in the United States and contributing to the outstanding share of revenue; thus, propelling the global cardiac arrest treatment market throughout the forecast period.

Cardiac Arrest Treatment Market

Competitive Landscape

The cardiac arrest market is moderately competitive and consists of several major players. Few of the key players are developing the novel product and technologies to compete with the existing products while others are acquiring and partnering with the other companies trending in the market. For instance, in January 2017, Abbott acquired St. Jude Medical and expanded its medical device segment globally by adding breakthrough inventions of SJM to its existing product portfolio of cardiovascular devices, such as the Quadra Allure MP CRT-P, used as cardiac resynchronization therapy in managing cardiac failure, which is further expected to foster the global cardiac arrest market growth throughout the forecast period. Some of the companies which are currently dominating the market are Koninklijke Philips NV, Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, and Novartis AG.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rise in Global Prevalence of Cardiac Disorders, such as Strokes and Coronary Heart Failures

      2. 4.2.2 Availability of Technologically Advanced Products and Reimbursement Policies

    3. 4.3 Market Restraints

      1. 4.3.1 Adoption of Minimally Invasive Procedures like Percutaneous Coronary Interventions

      2. 4.3.2 Lack of Advanced Healthcare Infrastructure, Skilled Professionals, and Highly Expensive Treatments

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Treatment

      1. 5.1.1 Drugs

        1. 5.1.1.1 Vasopressors

        2. 5.1.1.2 Anti-arrhythmic Drugs

        3. 5.1.1.3 Anticholinergic Drugs

        4. 5.1.1.4 Antihypertensives

        5. 5.1.1.5 Other Drugs

      2. 5.1.2 Medical Devices

        1. 5.1.2.1 Cardiac Resynchronization Therapy (CRT)

        2. 5.1.2.2 Defibrillators

        3. 5.1.2.3 Other Medical Devices

    2. 5.2 By Distribution Channel

      1. 5.2.1 Hospitals

      2. 5.2.2 Pharmacies

      3. 5.2.3 Other Distribution Channels

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United states

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Koninklijke Philips NV

      2. 6.1.2 Boston Scientific Corporation

      3. 6.1.3 GE Healthcare

      4. 6.1.4 Abbott Laboratories

      5. 6.1.5 Novartis International AG

      6. 6.1.6 Johnson & Johnson

      7. 6.1.7 Pfizer Inc.

      8. 6.1.8 Amgen Inc.

      9. 6.1.9 METsis Medikal

      10. 6.1.10 Medtronic PLC

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Cardiac Arrest Treatment Market market is studied from 2018 - 2026.

The Cardiac Arrest Treatment Market is growing at a CAGR of >4.8% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Koninklijke Philips N.V, Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Novartis AG are the major companies operating in Cardiac Arrest Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!